| Schedule of segment information |
| | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | | June 30, | | June 30, | | | | 2026 | | 2025 | | 2026 | | 2025 | | | | | (amounts, in thousands) | | | | | | | | | | | | | | | | Revenue | | $ | 9,633 | | $ | 9,617 | | $ | 18,497 | | $ | 18,344 | | Gross profit | | $ | 7,049 | | $ | 6,814 | | $ | 13,179 | | $ | 13,021 | | Gross margin | | | 73 | % | | 71 | % | | 71 | % | | 71 | % | Total operating expenses | | $ | 9,687 | | $ | 10,429 | | $ | 18,861 | | $ | 20,523 | | Loss from operations | | $ | (2,638) | | $ | (3,615) | | $ | (5,682) | | $ | (7,502) | | | | | | | | | | | | | | | | EBITDA and Adjusted EBITDA (both non-GAAP measures): | | | | | | | | | | | | | | Net income (loss) | | $ | (4,417) | | $ | 1,947 | | $ | (9,547) | | $ | 469 | | Interest expense, net | | | 868 | | | 616 | | | 1,726 | | | 1,221 | | Depreciation and amortization expense | | | 351 | | | 404 | | | 699 | | | 773 | | Earnings (Loss) before interest expense, income taxes, depreciation and amortization (“EBITDA”), a non-GAAP measure | | | (3,198) | | | 2,967 | | | (7,122) | | | 2,463 | | | | | | | | | | | | | | | | Stock-based compensation | | | 368 | | | 571 | | | 912 | | | 1,391 | | (Gain) loss on foreign currency transactions | | | 911 | | | (6,178) | | | 2,139 | | | (9,192) | | Restructuring | | | 270 | | | — | | | 310 | | | — | | Adjusted EBITDA, a non-GAAP measure | | $ | (1,648) | | $ | (2,640) | | $ | (3,761) | | $ | (5,338) | | | | | | | | | | | | | | | | Adjusted net loss, a non-GAAP measure: | | | | | | | | | | | | | | Net loss | | $ | (4,417) | | $ | 1,947 | | $ | (9,547) | | $ | 469 | | Stock-based compensation | | | 368 | | | 571 | | | 912 | | | 1,391 | | (Gain) loss on foreign currency transactions | | | 911 | | | (6,178) | | | 2,139 | | | (9,192) | | Restructuring | | | 270 | | | — | | | 310 | | | — | | Adjusted net loss, a non-GAAP measure | | $ | (2,868) | | $ | (3,660) | | $ | (6,186) | | $ | (7,332) | | | | | | | | | | | | | | | | Operating cash burn (net change in cash, cash equivalents, and restricted cash, excluding financing activities | | $ | (400) | | $ | (1,384) | | $ | (1,836) | | $ | (4,869) | |
| | | | | | | | | June 30, 2026 | | December 31, 2025 | | | | (amounts, in thousands) | Total assets | | $ | 37,960 | | $ | 44,182 |
| | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | | | (amounts, in thousands) | | (amounts, in thousands) | | | | | | | | | | | | | | Research and development: | | | | | | | | | | | | | Clinical expenses | | $ | 992 | | $ | 812 | | $ | 1,451 | | $ | 1,791 | Other research and development expenses | | | 461 | | | 450 | | | 1,027 | | | 1,133 | Total research and development | | $ | 1,453 | | $ | 1,262 | | $ | 2,478 | | $ | 2,924 | | | | | | | | | | | | | | Selling, general and administrative | | | | | | | | | | | | | Royalty expense | | $ | 290 | | $ | 286 | | $ | 546 | | $ | 544 | Stock-based compensation | | | 368 | | | 429 | | | 912 | | | 1,056 | Legal, financial and consulting | | | 583 | | | 1,364 | | | 1,504 | | | 2,002 | Other general and administrative | | | 6,723 | | | 7,088 | | | 13,111 | | | 13,997 | Total selling, general and administrative | | $ | 7,964 | | $ | 9,167 | | $ | 16,073 | | $ | 17,599 |
|